샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784799

트라코마 치료 시장

Trachoma Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 285 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 트라코마 치료 시장은 2030년까지 7억 990만 달러에 이를 전망

2024년에 5억 3,470만 달러로 추정되는 트라코마 치료 세계 시장은 2024-2030년 분석 기간에 CAGR 4.8%로 성장하여 2030년에는 7억 990만 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 매크로 놀이 기구는 CAGR 3.8%를 나타내고, 분석 기간 종료시에는 2억 7,070만 달러에 이를 것으로 예상되고 있습니다. 테트라 사이 크린 부문의 성장률은 분석 기간중 CAGR 4.2%로 추정됩니다.

미국 시장은 1억 4,570만 달러로 추정되어 중국은 CAGR 7.5%를 보일 것으로 예측

미국의 트라코마 치료 시장은 2024년에 1억 4,570만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 7.5%로 2030년까지 1억 3,870만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.4%와 4.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.1%를 보일 전망입니다.

트라코마 치료 시장 동향과 촉진요인 정리

세계보건기구(WHO)의 노력과 새로운 치료제로 인해 트라코마 치료는 어떻게 진화하고 있는가?

트라코마는 전 세계적으로 실명을 유발하는 주요 감염성 질환으로, 특히 깨끗한 물과 위생시설에 대한 접근성이 제한적인 저소득 지역에서 여전히 큰 공중보건 문제로 대두되고 있습니다. 이 질병은 클라미디아 트라코마티스에 의해 발생하며 여러 단계를 거쳐 진행되어 치료하지 않으면 흉터가 생기고 시력을 잃을 수 있습니다. 세계보건기구(WHO)와 국제 트라코마 이니셔티브(International Trachoma Initiative)와 같은 조직이 주도하는 트라코마 퇴치를 위한 세계 노력은 SAFE 전략(수술, 항생제, 얼굴 청결, 환경 개선)을 통해 치료에 대한 접근성을 크게 향상시켰습니다. 아지트로마이신의 대량 투여(MDA)는 감염률 감소와 합병증 예방이라는 획기적인 효과를 가져왔습니다. 그러나 항생제 내성, 재감염 위험, 유행 지역의 의료 인프라 부족 등의 문제는 여전히 남아있습니다. 세계보건기구(WHO)가 2030년 퇴치 목표를 향해 나아가고 있는 가운데, 치료제, 진단 및 공중보건 개입의 발전은 트라코마 관리를 어떻게 개선할 수 있을까요?

어떤 기술 혁신이 트라코마 치료를 발전시키고 있는가?

트라코마 치료의 새로운 개발은 항생제 투여 방법 개선, 수술 결과 개선, 백신 기반 예방 전략 개발에 초점을 맞추었습니다. AI를 활용한 진단 도구는 감염병을 조기에 발견하여 적시에 개입할 수 있도록 돕고 있습니다. 아지트로마이신의 단회투여, 장기지속형 제제는 순응도 및 치료 효과를 개선하기 위해 연구되고 있습니다. 흡수성 봉합사, 레이저를 이용한 시술 등 최소침습적 수술기법으로 속눈썹 난생증 치료의 합병증이 감소하고 있습니다. 또한, 트라코마에 특화된 백신 연구가 진행 중이며, 장기적인 면역을 제공하고 감염의 사슬을 끊는 것을 목표로 하고 있습니다.

왜 트라코마 치료에 대한 수요가 증가하는가?

소외된 열대성 질환(NTDs)에 대한 전 세계적인 노력 증가, 국제 보건기구의 자금 지원 증가, 항생제 유통망 개선 등이 트라코마 치료 수요를 촉진하고 있습니다. 위생 교육 프로그램의 확대는 질병 퇴치를 위한 노력에 더욱 박차를 가하고 있습니다. 또한, 모바일 헬스(mHealth) 솔루션의 발전은 더 나은 질병 모니터링을 가능하게 하고, 원격지 커뮤니티의 지원 활동을 향상시키고 있습니다.

트라코마 치료 시장의 성장을 가속하는 요인은 무엇인가?

NTD 퇴치를 위한 세계 보건 기금, 항생제 기반 대량 약물 투여 증가, 진단 및 수술 기술의 발전, 공중 보건 인프라의 개선으로 인해 시장이 확대되고 있습니다. 전염병이 유행하는 지역의 의료 접근성이 개선됨에 따라 트라코마 퇴치 노력이 가속화되고 전 세계적으로 실명률이 크게 감소할 것으로 예측됩니다.

부문

약제 클래스별(Macrolides, Tetracycline, Ophthalmic Anti-Infective, Sulfonamides);투여 경로별(경구제, 국소제)

조사 대상 기업 예

  • AbbVie Inc.
  • Advancing Chemical Industries(ACI)
  • Apotex Inc.
  • Arbor Pharmaceuticals(Azurity Pharmaceuticals)
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.(Viatris)
  • Novartis AG
  • Pfizer Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.12

Global Trachoma Treatment Market to Reach US$709.9 Million by 2030

The global market for Trachoma Treatment estimated at US$534.7 Million in the year 2024, is expected to reach US$709.9 Million by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Macrolides, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$270.7 Million by the end of the analysis period. Growth in the Tetracycline segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$145.7 Million While China is Forecast to Grow at 7.5% CAGR

The Trachoma Treatment market in the U.S. is estimated at US$145.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$138.7 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Trachoma Treatment Market Trends & Drivers Summarized

How Is Trachoma Treatment Evolving with Global Health Initiatives and Novel Therapeutics?

Trachoma, the leading infectious cause of blindness worldwide, remains a major public health concern, particularly in low-income regions with limited access to clean water and sanitation. The disease, caused by Chlamydia trachomatis, progresses through multiple stages, leading to scarring and vision loss if untreated. The global effort to eliminate trachoma, led by organizations such as the World Health Organization (WHO) and the International Trachoma Initiative, has significantly improved treatment accessibility through the SAFE strategy-Surgery, Antibiotics, Facial cleanliness, and Environmental improvements. Azithromycin mass drug administration (MDA) has been a game-changer, reducing transmission rates and preventing complications. However, challenges such as antibiotic resistance, reinfection risks, and lack of healthcare infrastructure in endemic areas persist. As global health organizations push toward the 2030 elimination goal, how will advancements in therapeutics, diagnostics, and public health interventions further improve trachoma management?

What Technological Innovations Are Advancing Trachoma Treatment?

New developments in trachoma treatment focus on improving antibiotic delivery, enhancing surgical outcomes, and developing vaccine-based prevention strategies. AI-driven diagnostic tools are helping identify early-stage infections, ensuring timely intervention. Single-dose, long-acting azithromycin formulations are being explored to improve compliance and treatment efficacy. Minimally invasive surgical techniques, including absorbable sutures and laser-based procedures, are reducing complications in trichiasis correction. Additionally, ongoing research into trachoma-specific vaccines aims to provide long-term immunity and break the cycle of transmission.

Why Is the Demand for Trachoma Treatment Increasing?

The rising global commitment to neglected tropical diseases (NTDs), increasing funding from international health organizations, and improvements in antibiotic distribution networks are driving demand for trachoma treatment. The expansion of sanitation and hygiene education programs is further supporting disease control efforts. Additionally, advancements in mobile health (mHealth) solutions are enabling better disease surveillance, improving outreach in remote communities.

What Factors Are Driving the Growth of the Trachoma Treatment Market?

The market is expanding due to global health funding for NTD eradication, increasing adoption of antibiotic-based mass drug administration, advancements in diagnostic and surgical techniques, and improvements in public health infrastructure. As healthcare accessibility improves in endemic regions, trachoma elimination efforts are expected to accelerate, significantly reducing blindness rates worldwide.

SCOPE OF STUDY:

The report analyzes the Trachoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Macrolides, Tetracycline, Ophthalmic Anti-Infective, Sulfonamides); Administration Route (Oral, Topical)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Advancing Chemical Industries (ACI)
  • Apotex Inc.
  • Arbor Pharmaceuticals (Azurity Pharmaceuticals)
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V. (Viatris)
  • Novartis AG
  • Pfizer Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Trachoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • WHO-Led Elimination Campaigns Spur Global Procurement and Distribution of Antibiotics
    • Increasing Deployment of Mass Drug Administration (MDA) in Endemic Regions Enhances Treatment Access
    • Advancements in Azithromycin Distribution Logistics Improve Supply Chain Resilience
    • Integration of Trachoma Programs With Broader NTD (Neglected Tropical Disease) Strategies Gains Momentum
    • Expansion of SAFE Strategy (Surgery, Antibiotics, Facial Cleanliness, Environmental Improvements) Enhances Impact
    • Partnerships Between Governments, NGOs, and Pharma Drive Resource Mobilization
    • Mobile Surgery Units and Training Programs Expand Access to Corrective Procedures
    • R&D in Resistance Monitoring and Dosing Protocols Strengthens Long-Term Efficacy
    • Improved Diagnostic Screening in School-Age Children Supports Early Detection and Treatment
    • Greater Involvement of Local Health Workers in Surveillance and Delivery Improves Community Engagement
    • Availability of Donor-Funded Antibiotics Reduces Cost Barriers in Low-Income Countries
    • Growing Integration With Eye Health and Vision Care Initiatives Broadens Treatment Reach
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Trachoma Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Trachoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ophthalmic Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ophthalmic Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ophthalmic Anti-Infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sulfonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sulfonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Sulfonamides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • JAPAN
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • CHINA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • EUROPE
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Trachoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • FRANCE
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • GERMANY
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Trachoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • INDIA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Trachoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Trachoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Trachoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030
  • AFRICA
    • Trachoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Trachoma Treatment by Drug Class - Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Trachoma Treatment by Drug Class - Percentage Breakdown of Value Sales for Macrolides, Tetracycline, Ophthalmic Anti-Infective and Sulfonamides for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Trachoma Treatment by Administration Route - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Trachoma Treatment by Administration Route - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Trachoma Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제